FIELD: chemistry.
SUBSTANCE: description is given of a lactam-containing compound-derivative of tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide with formula I 
, its pharmaceutical salt and pharmaceutical compositions, their content, and their use as Xa factor inhibitors. The given compound can be used for treating thromboembolic diseases.
EFFECT: obtaining a lactam-containing compound, which can be used for treating thromobembolic diseases.
42 cl, 9 tbl, 140 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2813780C2 |
| NEW COMBINATIONS OF KLOPIDOGREL-CONTAINING ACTIVE AGENT AND ANTITHROMBOSIS AGENT | 1997 |
|
RU2184547C2 |
| CRYSTALLINE FORMS OF KNOWN PYRROLIDINE INHIBITOR OF XA FACTOR | 2006 |
|
RU2368610C2 |
| DIHYDROINDOLYSINONE DERIVATIVE | 2015 |
|
RU2707887C2 |
| METHOD OF THROMBOSIS TREATMENT OR PREVENTION WITH APPLICATION OF DABIGATRAN ETEXILATE OR ITS SALT WITH IMPROVED EFFICIENCY IN COMPARISON WITH STANDARD TREATMENT WITH WARFARIN | 2009 |
|
RU2530645C2 |
| PHARMACEUTICAL COMBINATIONS | 2000 |
|
RU2242232C2 |
| COMBINATION OF THROMBOLYTICALLY ACTIVE PROTEINS AND ANTICOAGULANTS | 1995 |
|
RU2166326C2 |
| METHODS OF TREATING OR PREVENTING THROMBOSIS OR EMBOLISM | 2011 |
|
RU2611662C2 |
| ANTITHROMBOTIC COMPOUND | 2012 |
|
RU2604733C2 |
| PHARMACEUTICAL COMBINATIONS | 2002 |
|
RU2331422C2 |
